Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart; Per Ljungman; Rafael de la Camara; Gloria Tridello; Valentín Ortiz-Maldonado; Alvaro Urbano-Ispizua; Pere Barba; Mi Kwon; Dolores Caballero; Pierre Sesques; Emmanuel Bachy; Roberta di Blasi; Catherine Thieblemont; Friso Calkoen; Pim Mutsaers; Johan Maertens; Livia Giannoni; Emma Nicholson; Matthew Collin; Carlos Pinho Vaz; Elisabetta Metafuni; Joaquin Martinez-Lopez; Fiona L. Dignan; Josep-Maria Ribera; Arnon Nagler; Frantisek Folber; Robin Sanderson; Adrian Bloor; Fabio Ciceri; Nina Knelange; Francis Ayuk; Nicolaus Kroger; Marie José Kersten; Stephan Mielke

doi:https://doi.org/10.1038/s41375-021-01466-0

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart, Per Ljungman, Rafael de la Camara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta di Blasi, Catherine Thieblemont, Friso Calkoen, Pim Mutsaers, Johan Maertens, Livia Giannoni, Emma Nicholson, Matthew Collin, Carlos Pinho VazElisabetta Metafuni, Joaquin Martinez-Lopez, Fiona L. Dignan, Josep-Maria Ribera, Arnon Nagler, Frantisek Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis Ayuk, Nicolaus Kroger, Marie José Kersten, Stephan Mielke

Research output: Contribution to journal › Article › Academic › peer-review

73 Citations (Scopus)

Original language	English
Pages (from-to)	3585-3588
Number of pages	4
Journal	Leukemia
Volume	35
Issue number	12
Early online date	2021
DOIs	https://doi.org/10.1038/s41375-021-01466-0
Publication status	Published - Dec 2021

Access to Document

https://doi.org/10.1038/s41375-021-01466-0

Cite this

Spanjaart, A. M., Ljungman, P., de la Camara, R., Tridello, G., Ortiz-Maldonado, V., Urbano-Ispizua, A., Barba, P., Kwon, M., Caballero, D., Sesques, P., Bachy, E., di Blasi, R., Thieblemont, C., Calkoen, F., Mutsaers, P., Maertens, J., Giannoni, L., Nicholson, E., Collin, M., ... Mielke, S. (2021). Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia, 35(12), 3585-3588. https://doi.org/10.1038/s41375-021-01466-0

Spanjaart, Anne Mea ; Ljungman, Per ; de la Camara, Rafael et al. / Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies : results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. In: Leukemia. 2021 ; Vol. 35, No. 12. pp. 3585-3588.

@article{2ce15163e54544788ed28a86e6992ee4,

title = "Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group",

author = "Spanjaart, {Anne Mea} and Per Ljungman and {de la Camara}, Rafael and Gloria Tridello and Valent{\'i}n Ortiz-Maldonado and Alvaro Urbano-Ispizua and Pere Barba and Mi Kwon and Dolores Caballero and Pierre Sesques and Emmanuel Bachy and {di Blasi}, Roberta and Catherine Thieblemont and Friso Calkoen and Pim Mutsaers and Johan Maertens and Livia Giannoni and Emma Nicholson and Matthew Collin and Vaz, {Carlos Pinho} and Elisabetta Metafuni and Joaquin Martinez-Lopez and Dignan, {Fiona L.} and Josep-Maria Ribera and Arnon Nagler and Frantisek Folber and Robin Sanderson and Adrian Bloor and Fabio Ciceri and Nina Knelange and Francis Ayuk and Nicolaus Kroger and Kersten, {Marie Jos{\'e}} and Stephan Mielke",

note = "Funding Information: There is no financial support for this work that could have influenced the outcomes described in the paper. However, particular authors report a potential competing interests, which is described below. VOM has received compensation for travel support from Kite/Gilead, Novartis, BMS/Celgene, Takeda and Janssen and consultant or advisory fees from Kite/Gilead, Novartis, BMS/Celgene and compensation for presentations from Kite/Gilead. PB has received honoraria from Amgen, BMS, Gilead, Incyte, Miltenyi Biotec, Novartis and Pfizer and funding from the Carlos III Health Institute FIS16/01433 and 20/00197, Asociaci{\'o}n Espa{\~n}ola contra el C{\'a}ncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). MK has received consultancy fees and honoraria from Novartis, BMS/ Cellgene, Kite/Gilead, and Pfizer. PS has received honoraria from Kite/Gilead, Novartis, and Chugai. RDB has received honoraria/hospitality from Gilead, Novartis, and Janssen. CT has received consultancy fees, advisory fees and honoraria from Novartis, BMS/Celgene, Roche, Janssen, Takeda, Kite/Gilead, Incyte and research funding from Roche and travel expenses from Novartis, BMS/Celgene, Roche, Janssen, Kite/Gilead. PM has received research funding from Astra Zeneca and consultancy fees from BMS/ Celgene. EN has received research funding from Kite/Gilead, advisory board fees for Novartis and BMS/Celgene, travel support from Novartis and Kite/Gilead, speaker fees from Kite/Gilead. JML has received consultancy fees from Janssen, BMS, Novartis, Incyte, Roche, GSK and Pfizer and research funding from Roche, Novartis, Incyte, Astellas, and BMS. JMR received consultancy and speaker fees from Pfizer, Amgen, Shire, Ariad, Takeda and Novartis and research funding from Phizer, Amgen, Ariad, and Takeda. RS has received speakers fees and honoraria from Kite/Gilead and Novartis. AB has received honoraria from Kite/Gilead and Novartis. FA has received research funding from Mallinckrodt/ThekarosHonoraria from Novartis, BMS/Celgene, Janssen, Takeda, Mallinckrodt/Thekaros, Kite/Gilead, and Miltenyi Biomedicine. NK has received a research grant and honoraria from Novartis, Kite/Gilead, and BMS. SM has received funding from Celgene/BMS: Speakers bureau (via my institution); Novartis: Speakers bureau (via my institution); Gilead/Kite: Other: Travel support, Expert panel (via my institution); DNA Prime SA and funding from Speakers bureau (via my institution); Miltenyi: Other: Data safety monitoring board (via my institution) Immunicum: Other: Data safety monitoring board (via my institution). MJK has received research funding from Kite/Gilead and compensation for advisory boards and presentations and/or travel support from Kite/Gilead, Novartis, BMS/Celgene, and Miltenyi Biotec (to institution).",

year = "2021",

month = dec,

doi = "https://doi.org/10.1038/s41375-021-01466-0",

language = "English",

volume = "35",

pages = "3585--3588",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

Spanjaart, AM, Ljungman, P, de la Camara, R, Tridello, G, Ortiz-Maldonado, V, Urbano-Ispizua, A, Barba, P, Kwon, M, Caballero, D, Sesques, P, Bachy, E, di Blasi, R, Thieblemont, C, Calkoen, F, Mutsaers, P, Maertens, J, Giannoni, L, Nicholson, E, Collin, M, Vaz, CP, Metafuni, E, Martinez-Lopez, J, Dignan, FL, Ribera, J-M, Nagler, A, Folber, F, Sanderson, R, Bloor, A, Ciceri, F, Knelange, N, Ayuk, F, Kroger, N, Kersten, MJ & Mielke, S 2021, 'Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group', Leukemia, vol. 35, no. 12, pp. 3585-3588. https://doi.org/10.1038/s41375-021-01466-0

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. / Spanjaart, Anne Mea; Ljungman, Per; de la Camara, Rafael et al.
In: Leukemia, Vol. 35, No. 12, 12.2021, p. 3585-3588.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies

T2 - results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

AU - Spanjaart, Anne Mea

AU - Ljungman, Per

AU - de la Camara, Rafael

AU - Tridello, Gloria

AU - Ortiz-Maldonado, Valentín

AU - Urbano-Ispizua, Alvaro

AU - Barba, Pere

AU - Kwon, Mi

AU - Caballero, Dolores

AU - Sesques, Pierre

AU - Bachy, Emmanuel

AU - di Blasi, Roberta

AU - Thieblemont, Catherine

AU - Calkoen, Friso

AU - Mutsaers, Pim

AU - Maertens, Johan

AU - Giannoni, Livia

AU - Nicholson, Emma

AU - Collin, Matthew

AU - Vaz, Carlos Pinho

AU - Metafuni, Elisabetta

AU - Martinez-Lopez, Joaquin

AU - Dignan, Fiona L.

AU - Ribera, Josep-Maria

AU - Nagler, Arnon

AU - Folber, Frantisek

AU - Sanderson, Robin

AU - Bloor, Adrian

AU - Ciceri, Fabio

AU - Knelange, Nina

AU - Ayuk, Francis

AU - Kroger, Nicolaus

AU - Kersten, Marie José

AU - Mielke, Stephan

N1 - Funding Information: There is no financial support for this work that could have influenced the outcomes described in the paper. However, particular authors report a potential competing interests, which is described below. VOM has received compensation for travel support from Kite/Gilead, Novartis, BMS/Celgene, Takeda and Janssen and consultant or advisory fees from Kite/Gilead, Novartis, BMS/Celgene and compensation for presentations from Kite/Gilead. PB has received honoraria from Amgen, BMS, Gilead, Incyte, Miltenyi Biotec, Novartis and Pfizer and funding from the Carlos III Health Institute FIS16/01433 and 20/00197, Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). MK has received consultancy fees and honoraria from Novartis, BMS/ Cellgene, Kite/Gilead, and Pfizer. PS has received honoraria from Kite/Gilead, Novartis, and Chugai. RDB has received honoraria/hospitality from Gilead, Novartis, and Janssen. CT has received consultancy fees, advisory fees and honoraria from Novartis, BMS/Celgene, Roche, Janssen, Takeda, Kite/Gilead, Incyte and research funding from Roche and travel expenses from Novartis, BMS/Celgene, Roche, Janssen, Kite/Gilead. PM has received research funding from Astra Zeneca and consultancy fees from BMS/ Celgene. EN has received research funding from Kite/Gilead, advisory board fees for Novartis and BMS/Celgene, travel support from Novartis and Kite/Gilead, speaker fees from Kite/Gilead. JML has received consultancy fees from Janssen, BMS, Novartis, Incyte, Roche, GSK and Pfizer and research funding from Roche, Novartis, Incyte, Astellas, and BMS. JMR received consultancy and speaker fees from Pfizer, Amgen, Shire, Ariad, Takeda and Novartis and research funding from Phizer, Amgen, Ariad, and Takeda. RS has received speakers fees and honoraria from Kite/Gilead and Novartis. AB has received honoraria from Kite/Gilead and Novartis. FA has received research funding from Mallinckrodt/ThekarosHonoraria from Novartis, BMS/Celgene, Janssen, Takeda, Mallinckrodt/Thekaros, Kite/Gilead, and Miltenyi Biomedicine. NK has received a research grant and honoraria from Novartis, Kite/Gilead, and BMS. SM has received funding from Celgene/BMS: Speakers bureau (via my institution); Novartis: Speakers bureau (via my institution); Gilead/Kite: Other: Travel support, Expert panel (via my institution); DNA Prime SA and funding from Speakers bureau (via my institution); Miltenyi: Other: Data safety monitoring board (via my institution) Immunicum: Other: Data safety monitoring board (via my institution). MJK has received research funding from Kite/Gilead and compensation for advisory boards and presentations and/or travel support from Kite/Gilead, Novartis, BMS/Celgene, and Miltenyi Biotec (to institution).

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85118627482&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41375-021-01466-0

DO - https://doi.org/10.1038/s41375-021-01466-0

M3 - Article

C2 - 34750508

SN - 0887-6924

VL - 35

SP - 3585

EP - 3588

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Spanjaart AM, Ljungman P, de la Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021 Dec;35(12):3585-3588. Epub 2021. doi: https://doi.org/10.1038/s41375-021-01466-0

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Access to Document

Other files and links

Cite this